abstract |
Compounds according to the general formula (I) wherein X 1 , X 2 , X 3 and X 4 independently from each other are N or CR 8 wherein R 8 may be same or different, and wherein up to 3 of the group X 1 , X 2 , X 3 and X 4 may be N; A is a 5- or 6-membered aromatic or heteroaromtic cycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S wherein A may be substituted by 1 to 5 substituents R which may be same or different; their solvates, hydrates, and pharmaceutically acceptable salts for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal selected from a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis). |